News summary

Galimedix outlines phase 2a plans for GAL-101 in Alzheimer’s

Source: Longevity Technology • Published: 19 Nov 2026, 12:36

Summarized by Masters of Longevity from Longevity Technology.

Galimedix announced plans for a biomarker‑driven Phase 2a study of oral GAL‑101.

Galimedix outlines phase 2a plans for GAL-101 in Alzheimer’s
Key Takeaways
  • Galimedix plans a biomarker‑driven Phase 2a trial called SAPHARY.
  • They will test GAL‑101 in Down syndrome‑associated Alzheimer’s proof‑of‑concept.
  • The planned study is observationally biomarker‑driven and not causal proof.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.